Familial Hypomagnesemia with Hypercalciuria, Nephrocalcinosis, and Bilateral Chorioretinal Atrophy in a Patient with Homozygous p.G75S Variant in CLDN19.
{"title":"Familial Hypomagnesemia with Hypercalciuria, Nephrocalcinosis, and Bilateral Chorioretinal Atrophy in a Patient with Homozygous p.G75S Variant in <i>CLDN19</i>.","authors":"Nasim Rahmani, Saeed Talebi, Nakysa Hooman, Arezou Karamzade","doi":"10.1055/s-0041-1733852","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction</b> Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is a rare disorder caused by perturbation in renal reabsorption of magnesium and calcium. Biallelic pathogenic variants either in gene <i>CLDN16</i> or <i>CLDN19</i> are responsible for molecular defects. Most patients with <i>CLDN19</i> variants have been associated with ocular involvements (FHHNCOI). <b>Patient and Methods</b> We had a pediatric patient with hypercalciuric hypomagnesemia and bilateral chorioretinal atrophy. Metabolic profiling and radiology examinations were performed, in addition to whole exome sequencing (WES) used for detection of the causative variant. <b>Results</b> Analysis of WES revealed a homozygous c.223G > A (p.G75S) variant in <i>CLDN19</i> . MutationTaster and Combined Annotation-Dependent Depletion support its deleterious effect and SHERLOC's criteria put it in pathogenic category. This variant is previously reported in compound heterozygous state with other known pathogenic variant. As far as we know, it is the first report of this variant in homozygous state. <b>Conclusion</b> The variant found in our patient is pathogenic and compatible with FHHNCOI characteristics. WES is an advantageous tool in molecular diagnosis and finding genetic pathology of this disease. In line with other reports, ocular abnormalities are variable in patients with <i>CLDN19</i> mutations, and chronic kidney disease and retinal damages must be considered in this group.</p>","PeriodicalId":16695,"journal":{"name":"Journal of pediatric genetics","volume":"10 3","pages":"230-235"},"PeriodicalIF":0.4000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416216/pdf/10-1055-s-0041-1733852.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pediatric genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0041-1733852","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is a rare disorder caused by perturbation in renal reabsorption of magnesium and calcium. Biallelic pathogenic variants either in gene CLDN16 or CLDN19 are responsible for molecular defects. Most patients with CLDN19 variants have been associated with ocular involvements (FHHNCOI). Patient and Methods We had a pediatric patient with hypercalciuric hypomagnesemia and bilateral chorioretinal atrophy. Metabolic profiling and radiology examinations were performed, in addition to whole exome sequencing (WES) used for detection of the causative variant. Results Analysis of WES revealed a homozygous c.223G > A (p.G75S) variant in CLDN19 . MutationTaster and Combined Annotation-Dependent Depletion support its deleterious effect and SHERLOC's criteria put it in pathogenic category. This variant is previously reported in compound heterozygous state with other known pathogenic variant. As far as we know, it is the first report of this variant in homozygous state. Conclusion The variant found in our patient is pathogenic and compatible with FHHNCOI characteristics. WES is an advantageous tool in molecular diagnosis and finding genetic pathology of this disease. In line with other reports, ocular abnormalities are variable in patients with CLDN19 mutations, and chronic kidney disease and retinal damages must be considered in this group.
家族性低镁血症合并高钙尿和肾钙质沉着症(FHHNC)是一种罕见的疾病,由肾脏对镁和钙的重吸收紊乱引起。基因CLDN16或CLDN19的双等位致病变异是导致分子缺陷的原因。大多数患有CLDN19变异的患者与眼部受累(FHHNCOI)有关。患者和方法我们有一个儿童患者高钙低镁血症和双侧绒毛膜视网膜萎缩。除了用于检测致病变异的全外显子组测序(WES)外,还进行了代谢谱分析和放射学检查。结果WES分析显示CLDN19存在c.223G > a (p.G75S)纯合子变异。MutationTaster和组合注释依赖耗尽支持其有害作用,SHERLOC的标准将其列入致病性类别。该变异先前报道与其他已知致病变异呈复合杂合状态。据我们所知,这是首次报道该变异处于纯合状态。结论本例患者的变异具有致病性,符合FHHNCOI的特征。WES是该病分子诊断和发现遗传病理的有利工具。与其他报道一致,CLDN19突变患者的眼部异常是可变的,在该组中必须考虑慢性肾脏疾病和视网膜损伤。
期刊介绍:
The Journal of Pediatric Genetics is an English multidisciplinary peer-reviewed international journal publishing articles on all aspects of genetics in childhood and of the genetics of experimental models. These topics include clinical genetics, molecular genetics, biochemical genetics, medical genetics, dysmorphology, teratology, genetic counselling, genetic engineering, formal genetics, neuropsychiatric genetics, behavioral genetics, community genetics, cytogenetics, hereditary or syndromic cancer genetics, genetic mapping, reproductive genetics, fetal pathology and prenatal diagnosis, multiple congenital anomaly syndromes, and molecular embryology of birth defects. Journal of Pediatric Genetics provides an in-depth update on new subjects and current comprehensive coverage of the latest techniques used in the diagnosis of childhood genetics. Journal of Pediatric Genetics encourages submissions from all authors throughout the world. The following articles will be considered for publication: editorials, original and review articles, short report, rapid communications, case reports, letters to the editor, and book reviews. The aim of the journal is to share and disseminate knowledge between all disciplines in the field of pediatric genetics. This journal is a publication of the World Pediatric Society: http://www.worldpediatricsociety.org/ The Journal of Pediatric Genetics is available in print and online. Articles published ahead of print are available via the eFirst service on the Thieme E-Journals platform.